Sector News

Biogen partner Sobi and its Boston-based CEO field a takeover bid

April 28, 2015
Life sciences
Sweden’s Sobi, a close partner of Biogen, is in the crosshairs of a buyout bid. But the biotech isn’t saying yet just who’s doing the bidding.
 
In a release this morning the Stockholm-based Swedish Orphan Biovitrum, whose CEO moved to Boston last summer, confirmed “that it has received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company.”
 
Word of the proposed takeover has been circulating for several days. Bloomberg reported on the takeover buzz two days ago, which comes after the company brought in Goldman Sachs to advise it–a move akin to staking a “for sale” sign in the front yard. The company is currently valued at about $3.5 billion, though its shares surged about 24% as word of the buyout bid spread in a feverish market for biotech M&A.
 
Last year marked a major turning point for Sobi, which has a high profile in the small biotech world in Sweden. It’s partnered with Biogen ($BIIB) on hemophilia, and the Big Biotech won an approval last summer for Eloctate, part of a new wave of hemophilia drugs that has been changing the market. The approval for Eloctate, which is used to treat hemophilia A, followed an approval for Alprolix as a treatment for hemophilia B.
 
Its focus on rare diseases could attract a variety of suitors. Reuters speculated that Pfizer, which is a big buyer these days, may be in pursuit. Biogen Idec might scout for a deal at the right price. But with a market value of $3.5 billion, a number of larger outfits could fit the profile of a logical buyer.
 
Geoffrey McDonough was brought in to run Sobi in 2011 after a stint at Genzyme, another rare disease biotech. He was trained in Boston and returned there last fall, when the company opened an office in Waltham, MA.
 
By John Carroll
 

comments closed

Related News

November 19, 2022

Sequana announces results from study of direct sodium removal

Life sciences

Sequana, a company focusing on liver disease, heart failure and cancer has announced positive top-line results from SAHARA – the phase 2a study using its first-generation direct sodium removal (DSR) product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients confirmed long-lasting clinical benefits.

November 19, 2022

Bristol Myers Squibb opens 125-acre biologics campus in Dublin

Life sciences

Bristol Myers Squibb has officially opened its Cruiserath Biologics site in Dublin. The site, which represents a $1bn investment – was officially opened by the company’s chief executive officer, Giovanni Caforio, who arrived from New York, and site general manager Pádraig Keane.

November 19, 2022

Pharma must stay the course on Twitter as docs are not abandoning the platform yet: Report

Life sciences

Like it or loathe it, and whatever its new direction, Twitter is still a powerful platform for doctors, and pharma should not abandon the troubled social media site yet, according to a new report from healthcare consultants at ZoomRx.